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A B S T R A C T
Cancer pain, especially pain caused by metastasis to bone, is a severe type of pain, and unless the
cause and consequences can be resolved, the pain will become chronic. As detection and survival
among patients with cancer have improved, pain has become an increasing challenge, because
traditional therapies are often only partially effective. Until recently, knowledge of cancer pain
mechanisms was poor compared with understanding of neuropathic and inflammatory pain states.
We now view cancer-induced bone pain as a complex pain state involving components of both
inflammatory and neuropathic pain but also exhibiting elements that seem unique to cancer pain.
In addition, the pain state is often unpredictable, and the intensity of the pain is highly variable,
making it difficult to manage. The establishment of translational animal models has started to
reveal some of the molecular components involved in cancer pain. We present the essential
pharmacologic and neurobiologic mechanisms involved in the generation and continuance of
cancer-induced bone pain and discuss these in the context of understanding and treating patients.
We discuss changes in peripheral signaling in the area of tumor growth, examine spinal cord
mechanisms of sensitization, and finally address central processing. Our aim is to provide a
mechanistic background for the sensory characteristics of cancer-induced bone pain as a basis for
better understanding and treating this condition.
J Clin Oncol 32:1647-1654. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Pain is a multifaceted sensation involving the entire
nervous system. Pain processes usually start in the
periphery, where tissue or nerve damage arises as a
consequence of trauma, disease, or lesion, including
the growth of a tumor within tissue or nerves. Dif-
ferent patternsof electrical and chemical events then
transfer the painful messages via specialized nerves
through to the spinal cord, where, after integration
of the incoming messages, activity passes to many
parts of the brain through a series of increasingly
complex pathways. Each level is subject to enhance-
ment and modulation. With simple acute pain, the
peripheral and central processes are short-term,
temporary changes that resolve when the tissue
heals. By contrast, chronic pain is driven by long-
lasting, ongoing activity from the periphery that
produces more persistent changes within spinal
cord and brain circuits. In broad terms, pain can be
divided into inflammatory pain (also called nocice-
ptive pain), where the pain arises from chemical or
natural stimuli fromdamaged tissue (surgery,osteo-
arthritis, or trauma), and neuropathic pain, caused
by direct lesion or disease of the sensory nerves (di-
abetes or shingles). Here, the pain is predominantly
initiatedbychanges in the ionchannels thatproduce
action potential within the nerves. Thus, inflamma-
tory pain is initiated by chemical mediators, and
neuropathic pain is initiated by altered electrical
events (Fig 1). Table 1 lists the events that occur in
these types of pain and compares them with cancer
pain. Importantly, cancer-induced pain can involve
both inflammatory and neuropathic mechanisms,
because tumor expansion induces tissue damage
and release of various inflammatory mediators. In
addition, the cancer can also compress, growwithin
a sensory nerve, or denervate the target tissue, all
causing neuropathic changes. Cancer pain can be
considered a type of mixed pain, but increasing
amounts of evidence suggest additional unique fea-
tures indicating that it should be regarded as a sepa-
rate pain state.
CANCER PAIN
As advances in treatment and detection of cancer
have resulted in longer survival time, chronic pain
has become an increasing problem, significantly
compromising quality of life for many patients.10,11
Pain caused by metastasis to the bone is the most
common source of moderate and severe cancer
pain, and approximately 75% of patients with ad-
vanced cancer experience bone pain.12 Currently,
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only half experience temporary pain relief from conventional thera-
pies,10 a clear indication of the need for development of new and
better treatments.
Cancer-induced bone pain is a complex pain state involving a
combination of background, spontaneous, and incident (movement-
evoked) pain.13,14 Background pain, a dull continuous pain, increases
in intensity as the diseases progresses and can normally be treated
fairly successfullywith traditional analgesics. In contrast, spontaneous
and incidentpain, often referred to as breakthroughpain, are episodes
of extreme pain breaking through the therapeutic regimen adminis-
trated to control background pain.15,16 Their intermittent nature
makes these types of painhard to treat, because the episodes tend tobe
rapid in onset and of short duration, making currently used analgesic
therapies both insufficient and associated with dose-limiting ad-
verse effects.17,18
Cancer-induced bone pain is a mixed-mechanism pain state
exhibiting elements of both neuropathic and inflammatory pain, but
withdistinctivemodifications to the tissue andnerves in theperiphery
aswell as uniqueneurochemical changes at the spinal cord level. Thus,
it is a complex syndrome involving inflammatory, neuropathic, isch-
emic, and cancer-specific mechanisms, often occurring at more than
one site (Table 1). Inflammatory infiltrationoccurs as a result of direct
tissue damage caused by tumor growth as well as release of pain
mediators by the cancer cells. Theneuropathic component of the pain
can result from cancer-induced damage to the sensory nerves caused
by infiltration and/or compressionby the tumor cells, tumor-induced
hyperinnervation,19 and stretching or denervation as the bone ex-
pands anddegrades. In addition, neuropathy canarise as a subsequent
consequence of therapeutic intervention, such as chemotherapy or
surgery. The mechanisms behind the pathophysiology are both pe-
ripherally and centrally induced, with altered impulses from the bone
and surrounding tissues, resulting in a state of general hyperexcitabil-
ity of the neurons in the dorsal horn of the spinal cord. Interestingly,
the presence and intensity of the pain are not necessarily correlated
with the size or number of active malignancies; whereas some meta-
static sites are completely painless, others cause patients to experience
severe pain from a single bone metastasis, even in the absence of
fracture.16This is likely the resultofdifferentbalancesbetweenperiph-
eral and central mechanisms and the ability of central modulatory
systems to reduce peripheral activity, bothofwhich could vary among
patients. The unique neurochemical signature of cancer-induced
bone pain may explain the reduced efficacy of traditional analgesics,
suggesting that polypharmacyor alternative approachesmaybebetter
options for effective painmanagement.
Acute pain
Mechanical force
Chemical 
stimulation
Inflammatory pain
Inflammatory cells
Inflammatory
mediators
Tissue damage
Neuropathic pain
Loss or gain of function Central sensitization
Central sensitizationPeripheral sensitization
Heat
Cold
Fig 1. Diagram of three main types
of pain.
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ANIMAL MODELS
To meet the clinical need for better therapies, in vivo models accu-
rately mimicking the human condition have been developed. The
pivotal problem lies in identifying the role ofmolecules in theprocess-
ing of pain, in the context of the whole animal. Therefore, to achieve
these aims, in vivo models (ie, integrated systems) are essential to
study pain, because the interactions among peripheral activity, spinal
transmission, modulatory systems, and finally brain systems deter-
mine thenetoverall activity that leads to thefinalpain sensation.What
is currently known about cancer pain is based on detailed exploration
of the changes that occur to tissue, nerves, and surrounding structures
when tumor cells grow within a bone. Previously, animal models of
metastatic cancerwere based on systemic injection of carcinoma cells,
resulting in animals in poor health, unpredictable locations of multi-
ple bone metastases, and wide variability among animals.20,21 More
recently, the pain state has beenmodeled by direct injection of cancer
cells into the intramedullary space of long bones, resulting in transla-
tional models with site-specific metastases and characteristics reflect-
ing the clinical condition, with progressive tumor-induced bone
destruction, elevated osteoclast activity, and progressive and distinc-
tive nocifensive behavior.22 These models have enabled systematic
investigation of the molecular mechanisms involved and revealed
correlation of tumor growth and the surroundingmicroenvironment
of the tumorwithbonedestruction, site-specificnocifensive behavior,
and neurobiologic changes in the periphery and at the levels of the
spinal cord and brain.
Since the first model involving direct injection of sarcoma cells
into the femurs of mice was described in 1999, models have been
modifiedandrefinedusingdifferent species, bones, andcancer lines.22
Injection of tumor cells into different bones (femur, calcaneus, hu-
merus, and tibia23-28) result in pain conditions that seem similar in
nature and in which sex has only aminor effect on progression of the
pain state.29 In contrast, different types of cell lines cause distinct types
of behavior, bone destruction, and neurochemical reorganizations in
the spinal cord,demonstrating thatmultiplemechanismsare involved
in the generation and continuance of cancer-induced bone pain.25
PERIPHERAL MECHANISMS
Thebiologyof cancer-inducedbonepain involves a complex interplay
among the tumor cells, peripheral nerves, and cells of the bone (Fig 2).
Bone marrow, mineralized bone, and periosteum are highly inner-
vated by nerve fibers,30-33 and as the cancer cells invade the bone and
start proliferating,mechanical damage, distension, and entrapmentof
the primary afferent fibers lead to a neuropathic state. Additionally,
numerousnociceptiveand inflammatoryresponsesare triggered, sub-
sequently recruiting inflammatory cells such asmacrophages, neutro-
phils, and T cells,34 which release a plethora of stimuli acting on the
primary afferent fibers, bone cells, and cancer cells and initiate a
cascade of mechanisms, including activation and sensibilization of
nociceptors, degradation of bone, and tumor growth.34-38
As the disease advances, the cancer cells induce damage and
deformation of the peripheral nerves in the bone. The bone is inner-
vated by a tight network of both sympathetic and sensory neurons,
and although the periosteum has long been considered the most
densely innervated part of the bone, when total volume is considered,
the greatest number of nerve fibers are found in the bone marrow,
followed by the mineralized part of the bone and finally the perios-
teum.32,39,40 Innervation of the bone by various nerve fibers has been
established, and the size, neurochemistry, and segmental distribution
of the neuronal projection from the bone to the dorsal root ganglions
(DRGs) and dorsal horn have been demonstrated as consistent with
having functional roles in nociception.41 Confinement ofNCTC(Na-
tional Collection of Type Cultures) clone 2472 osteolytic tumor cells
Table 1. Mechanisms of Pain
Type of Pain Mechanism
Acute1,2 Activation of nociceptors by mechanical and thermal
stimuli
No long-term tissue or nerve damage
Normal healing
Normal transmission to spinal cord and brain
Activation of sensory areas of brain
Neuropathic3,4 Damage or lesion to sensory fibers or neurons
Denervation of spinal cord from periphery
Altered ion channel function
Gain and loss of somatosensory function
Increased compensatory spinal transmitter release
Induction of central sensitization and windup
Increased transmission to sensory and affective
brain areas
Loss of descending inhibition; gain of facilitation
Ongoing and evoked pain
Comorbidities
Inflammatory4-6 Chemical activation of nociceptors by mediators
Mediators produced by damaged tissue and
immune cells
Increased levels of cytokines and growth factors
Altered vascular events
Gain of somatosensory function
Peripheral sensitization
Enhanced inputs into spinal cord
Induction of central sensitization and windup
Increased transmission to sensory and affective
brain areas
Changes in descending inhibition; gain of facilitation
Ongoing and evoked pain
Comorbidities
Cancer7-9 Chemical activation of nociceptors by mediators
Mediators produced by damaged tissue and
immune cells
Increased levels of cytokines and growth factors
Increased innervation of tissue
Breakdown of bone
Altered vascular events
Gain of somatosensory function
Peripheral sensitization
Distention and denervation of sensory fibers or
neurons
Compression and invasion of nerves by tumor cells
Altered ion channel function
Enhanced inputs into spinal cord
Induction of central sensitization and windup
Increased transmission to sensory and affective
brain areas
Gain of descending facilitation
Ongoing and evoked pain
Comorbidities
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in mouse femur causes injury to both the myelinated and unmyeli-
nated sensory nerve fibers innervating the bone and marrow,42 and
recently, studies have shown that cancer cells in the bone induce
sprouting and reorganization of sensory and sympathetic fibers in the
periosteum.43 The highly disorganized sprouting causes a general in-
crease in nerve fiber density of both sensory and sympathetic nerve
fibers and formations of neuroma-like structures, similar to those
observed in conditions known to produce spontaneous ectopic pain
episodes, such as complex regional pain syndrome. Therefore, it has
been speculated that the neuroma-like structures caused by cancer
cells in the bone contribute to episodes of breakthrough pain or even
movement-induced pain.19,44 Thesemechanismsmight be linked not
only to changes in morphology but also to the reorganization of
sensory and sympathetic fibers. In normal healthy bone, sensory and
sympathetic fibers are separated; however, tumor-induced sprouting
causes an intermingling of the two fiber types, allowing sympathetic
fibers to potentially trigger nociceptive stimuli, exciting the nearby
sensory fibers.19 In addition, the sprouting and neuroma formation
are likely associated with the expression and release of nerve growth
factors (NGFs) by the tumor cells and tumor-associated cells. Thera-
peutic treatment with NGF-specific antibodies blocks sprouting and
attenuates pain without affecting tumor growth or bone destruction,
suggesting an important role for NGFs in driving bone cancer pain.43
This important evidence suggests that potential clinical interventions
could target NGFs, and indeed, tanezumab, despite some concerns
about adverse effects, has been shown to be effective in patients with
osteoarthritis and lower back pain45,46 and has potential for the treat-
ment and palliation of cancer pain.
In addition to direct nerve damage, cancer cells compromise the
mechanical strength of the bone. Under physiologic conditions, nor-
mal bone remodeling is balanced by formation of bone by osteoblasts
and resorption of bone by osteoclasts.47 Depending on the type of
cancer cells involved, either osteolytic (net resorption) or osteoblastic
(net deposition) bone lesions can occur, both compromising micro-
architecture and strength.48,49 Inmost metastatic cancers, net resorp-
tion of the bone occurs, resulting in bone less resistant to bending and
with increased risk of facture. Osteolytic lesions are caused by prolif-
eration and hypertrophy of osteoclasts, which in turn induce bone
remodelingby releasingvariousacidic and lytic enzymes, causingboth
degradationofboneandadecrease in thepHof the local environment
surrounding the tumor.47,49 It has been suggested that local acidosis,
causedbyproductionof extracellular protons,may alsobe involved in
sensitizing the primary afferents through activation of acid-sensitive
ion channels on the primary afferents in the bone50 (Fig 2).
The increased osteoclast proliferation and activation observed in
cancer-induced bone pain are connected to an increased production
and release of RANK ligand (RANK-L). RANK-L is normally ex-
pressed on various cell types, including osteoblasts, and is, in combi-
nationwith colony-stimulating factor-1 (CSF-1), essential for normal
proliferation and activation of osteoclasts through activation of the
RANK receptor expressed on osteoclast precursors.51,52 Interaction
between RANK-L and the RANK receptor is normally controlled by
osteoprotegrin (OPG), released by osteoblasts, which acts as a decoy
receptor for RANK-L and prevents its binding, thus inhibiting oste-
oclast activation. The tumor interrupts the normal balance between
RANK and RANK-L by increasing secretion of RANK-L from both
cancer cells and T cells,52,53 thus accelerating bone degradation. After
injectionofOPGintomicewithearly-stagedisease, tumorburdenwas
unaffected, but adramatic decrease innumberof osteoclasts andbone
destruction ensued. In addition, there was a significant decrease in
nocifensive behavior, and neurochemical changes normally intro-
duced in the spinal cordbycancer-inducedbonepainwere reversed.48
Various OPG-like peptidominetics and anti–RANK-L antibodies,
such as denosumad, have been tested in clinical trials, demonstrating
Bone
degradation
Immune
cells
Tumor cells
Inflammatory
mediators and
growth factors
Tissue
damage
Nerve damage
 • Compression
 • Distension
 • Hyperinnervation
 • Denervation
Peripheral nerve
 • Touch
 • Pressure
 • Temperature
 • Nociception
Cortical processing
 • Spatial
 • Temporal
 • Intensity
Limbic registration
 • Unpleasantness
Spinal events
 • Integration
 • Amplification
 • Modification
Central sensitization
 • Neuronal
   hyperexcitability
Brain stem modulation
 • Descending control Fig 2. Basic mechanisms of pain pro-
cesses at peripheral, spinal, and supraspi-
nal sites and influences of various
peripheral mechanisms, including tumor
cell– and immune cell–mediated release
of pronociceptive factors, direct tissue
damage, and bone degradation through
osteoclast activation. Because of periphe-
ral events, central excitability changes are
recruited. Combination of these events
produces final pain experience at highest
centers of brain.
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suppression of bone resorption in patients with different bone degen-
erative diseases, including cancer-induced bone diseases.54,55 Simi-
larly, bisphosphonates have been demonstrated to suppress bone
degradation and pain behavior in both animal models and in the
clinic.56 In both cases, pain relief is not directly related to inhibition of
nociception; rather, it is a more indirect effect caused by a decrease in
the osteolytic effect of the tumor.
The inflammatory infiltration associated with tumor growth
initiates a release of various growth factors, cytokines, interleukins,
chemokines, prostanoids, endothelins, and other mediators spec-
ulated to contribute to the development and/or maintenance of
pain34-38,57,58 (Fig 2). Although the inflammatory component is likely
only a partial contributor to the overall pain state, various nonsteroi-
dal anti-inflammatory drugs (NSAIDs) are commonly used in the
clinic as supplements to stronger analgesics so patients can benefit
from potential additive effects.59 NSAIDs produce analgesia through
inhibition of the cyclooxygenase (COX) pathway, thereby reducing
production of prostaglandins, and cancer cells and macrophages as-
sociated with bone tumors express high levels of COX-2.60,61 How-
ever, preclinical evidence seems conflicting. Some studies have shown
that selective COX-1 and COX-2 inhibitors have only little effect on
pain-related behavior in some animalmodels of cancer-inducedbone
pain,24,59 whereas others have demonstrated that both acute and
chronic administration of other COX-2 inhibitors reduce ongoing as
well as movement-evoked pain, in addition to effectively reducing
tumor burden and level of bone destruction.62-64 The differencesmay
be accounted for by the fact that different COX inhibitors and different
protocols of administration were employed in the studies. However,
there is still a general lack of clinical evidence to support a significant
analgesic effect of NSAIDs in cancer-induced bone pain.52,59
Other factors related to tissue damage and inflammation have
been studied toprovidenew therapeutic targets.Currently, purinergic
receptors, especially ATP receptors, have received much attention in
relation to chronic pain.65 ATP is found in all cells, so any tissue or
nervedamage is likely torelease thismediator.Purinergic receptorsare
divided intoP2Xreceptors, ligand-gated ionchannels, andP2Yrecep-
tors acting throughGprotein–coupledmechanisms.TheP2X3recep-
tor has been studied intensively in relation to pain; these receptors are
expressed selectively on small-diameter nociceptive fibers, whereas
many other purinergic receptors are diversely expressed in many dif-
ferent tissues throughout thebody.65 Electrophysiologic studies in rats
with cancer-inducedbonepainhavedemonstrated that both systemic
and spinal applications of a P2X3 and P2X2/3 antagonist, AF-353,
inhibit neuronal responses to electrical, mechanical, and thermal
stimulations as well as attenuate pain behavior.66 In addition, studies
using a different P2X3 and P2X2/3 antagonist have also shown a
reduction in pain behavior in bothmurine and rat models of cancer-
induced bone pain.67-69 These receptors have the potential to be novel
targets for analgesia.
Damage to the peripheral nerves and degradation of the bone, in
addition to tumor-related release of inflammatory mediators, can
cause sensitization of the nociceptors and/or neuropathy in the pe-
riphery, both significantly increasing the primary afferent drive to the
spinal cord. Because a major action of a number of drugs, including
opioids, is to counter these inputs as they enter the spinal cord, these
increased afferent messages may explain some of the difficulties in
controlling cancer pain.
CENTRAL MECHANISMS
There are unique neurochemical changes in the DRGs and dorsal
horn during cancer-induced pain,22,48 suggesting that peripheral
changes drive central spinal hypersensitive states of neurons project-
ing to thepartsof thebrain involved inpain sensation (Fig2).Changes
in neurons and glia cells in the dorsal horn indicate separate but
overlapping mechanisms with other chronic pain states. Whereas
inflammatory and neuropathic pain induce changes in substance P
and calcitonin gene-related peptide (CGRP) levels in the dorsal horn
and DRGs, these changes are absent in cancer-induced bone pain.48
Instead, increased expression of c-FOS and dynorphin are seen, espe-
cially in the deeper laminae of the dorsal horn, accompanied bymas-
sive spinal astrocyte hypertrophy and upregulation of activating
transcription factor 3 (ATF3) and galanin, markers of nerve damage,
in DRGs.42,48 The neurochemical changes correlate with tumor
growth and subsequent damage of the surrounding bone. However,
the finding that multiple metastases are not necessarily more painful
than single metastasis can be explained by the ability of the CNS to
dampen or modulate pain messages at central levels. Changes in
dynorphin and c-FOS expression have also been observed in inflam-
matory andneuropathic painmodels, suggesting similar components
contribute to parts of the cancer pain state.70,71
Spinal cord neurons in models of cancer-induced bone pain
show enhanced responses to evoked stimuli, reflecting a general hy-
perexcitability of the neurons, as has also been seen in inflammatory
and neuropathic states.72,73 In addition, there is an increase in the
receptivefield forneurons in the superficial dorsal horn andalteration
in the ratio between nociceptive-specific neurons and wide dynamic
range (WDR) neurons, features of central sensitization. Animals with
cancer-induced bone pain display an increased number ofWDRneu-
rons in the superficial dorsal horn, resulting in an increased probabil-
ity of response to low-threshold peripheral inputs; in contrast, WDR
neurons in the deeper dorsal horn display less pronounced changes,
although responses to thermal and electrical stimuli are significantly
increased.74 Even in animals chronically treated with morphine, the
abnormally high ratio of WDR cells persists, suggesting that there
remains greater access to low-threshold stimuli, whichmay be related
to the problem of controlling allodynia and breakthrough pain in the
clinic.75 Neurobiologic reorganization such as this seems unique to
cancer-induced bone pain and is not seen in inflammatory or neuro-
pathic models. Furthermore, chronic treatment with gabapentin,
which modulates calcium channels at the spinal level and so reduces
transmitter release fromafferents, temporarily attenuates plasticity by
shifting the abnormally high WDR-like population back to nocicep-
tive-specific–like cells and reducing the input of and C-fiber response
to electrical stimuli.74 Together this suggests that the phenotypical
shift in superficial dorsal hornneurons fromnociceptive-specificneu-
rons toWDR-likeneurons is linked to alterations in synapses fromthe
periphery to the spinal cord as well as in intrinsic signaling. On the
basis of this preclinical evidence, drugs such as gabapentin might be
useful agents.
In addition, spinal neurons show increased excitability; here, an
important factor is the N-methyl-D-aspartate (NMDA) receptor for
glutamate, the major excitatory transmitter in the nervous system,
found inalmost all painfibers.Activationof theNMDAreceptor leads
Mechanisms of Cancer-Induced Bone Pain
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towindup,where a constant stimulus elicits responses increased four-
to five-fold, although peripheral input remains the same. Thus,
windup is a plausible basis for what has been termed central sensitiza-
tion. Spinal neurons that become hyperexcitable show reduced
thresholds, increased receptive field sizes, and ongoing stimulus-
independent activity as well as greater evoked responses. This activity
is a likely basis for the allodynias, hyperalgesia, and spontaneous pain
seen in patients, because many of these spinal neurons project to higher
centers of the brain. Ketamine blocks theNMDA receptor complex, and
use of NMDA antagonists has been a useful tool for demonstration of
NMDA receptor–mediated hypersensitivity in patients with pain result-
ing from surgery, tissue damage, neuropathy, and fibromyalgia.76 Re-
cently, involvement of theNR2B receptor in behavioral consequences of
bone cancer pain has been demonstrated,77 and we have studied the
ability of antagonists at theNR2B receptor as well as ketamine to reduce
the altered neuronal responses provoked by bone cancer pain (Patel and
Dickenson, unpublisheddata).
Clinically, opioids remain the most effective pharmacologic
treatment for severe pain resulting from malignancy in the bone.
Opioids have a number of mechanisms related to analgesia, but a
major site is the spinal cord, where opioids reduce both painful inputs
and inhibit spinal neuronal activity.76 However, adverse effects asso-
ciated with the high doses required to significantly reduce episodes of
incident pain make opioid therapy far from perfect. Pharmacologic
studies have shown that the analgesic effects of opioids can be less
effective in cancer-induced bone pain compared with other pain
states.78-80 Treatment with morphine reduces pain behavior in ani-
mals with cancer-induced bone pain, although only in early-stage
disease involving mild to moderate pain intensity; as the severity
increases, the effectiveness of morphine is reduced, and the analgesic
effects are only observed with doses that also cause substantial ad-
verse effects.81,82
SUPRASPINAL MECHANISMS
After integration and modulation at the spinal level, the enhanced
pain messages are sent to the brain, where the final individual pain
experience is generated (Fig 2). Activity in both the sensory discrimi-
natory parts of the brain and the affective and emotional brain areas
will change in different pain states. The sensory aspects of pain are
established by activity in cortical areas through relays in the thalamus.
The equally important emotional or affective components of pain are
likely to be through inputs from spinal neurons to areas such as the
amygdala. Persistent inputs into the limbic brain areas, including the
amygdala, are likely to be causal regarding comorbidities that patients
often report resulting from ongoing pain that disrupt normal func-
tioning and generate fear, depression, and sleep problems. Finally,
pain alters function and activity in the descending controls, which
relay information from higher brain centers via the midbrain and
brainstem to the spinal cord. Thus, a reciprocal relationship exists,
wherebymood, anxiety, and so on can influence pain. These descend-
ing controls link the higher parts of the brain back to the spinal cord
and are controlled by areas such as the amygdala.83 Descending path-
ways run from the central gray to brainstem nuclei, where the final
projections to the spinal cord originate. Cells in these areas allow the
brain to generate descending excitation or inhibition. The balance in
acute pain states shifts in pathophysiologic pain models so that exci-
tation dominates. Thus, loss of inhibition or gain of facilitation pro-
motes pain, whereas evoking inhibition reduces pain. Preclinical
studies have suggested that thebases for this aredescendingnoradren-
ergic, mostly inhibitory, and certain serotonergic controls that facili-
tate pain. These monoamine descending controls regulate spinal
neuronal activity bidirectionally and underlie the efficacy of antide-
pressants for the treatment of pain.84 Little has been done regarding
descending controls in cancer pain models, but blocking the 5HT3
receptor attenuates descending excitatory controls from the brain to
the spinal cord and reduces the response of superficial dorsal horn
WDR-like cells to thermal and mechanical stimuli.73 This strongly
suggests thatpartof the increased spinal excitability seen in thecancer-
induced bone pain model is not simply peripheral or spinal but that
abnormal descending controls contribute to the changes. These alter-
ations would suggest that central changes are important, and of
course, these may be partly driven by limbic changes, themselves
subserving comorbidities common in patients, such as fear, sleep
problems, and depression.
Thus, a series of molecular and neurobiologic changes occur in
models of cancer-induced bone pain. These overlapwith changes that
have been observed in states of inflammatory pain and pain after
neuropathy. These pathologic events start in the periphery and con-
tinue into the spinal cord and brain, where finally, there are altered
descending controls back to the spinal cord. However, additional
changes ensue so that cancer-induced bone pain has unique charac-
teristics. Taken as awhole, these series of altered processes can explain
the ongoing pain, altered sensory perceptions, such as allodynias and
hyperalgesias, and comorbidities so common in patients. This com-
plexitymay seemdauntingand is abasis for the issues seen in the clinic
in terms of treating pain. However, this same complexity and mix of
inflammatory andneuropathic components offer treatmentopportu-
nities, where drugs with actions in different indicationsmay be effica-
cious. Finally, the existence of multiple mechanisms provides a
rational basis for the use of combination therapy in cases where a
single agent is not enough.
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